Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now? [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
In this article, we will summarize the bulls' thesis on IBRX. ImmunityBio, Inc.'s share was trading at $10.00 as of March 3rd. TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. IBRX is being positioned as a high-conviction bullish setup driven by an unusual combination of extreme short interest, accelerating fundamentals, and a rapid cadence of clinical and regulatory catalysts. The stock currently carries short interest of roughly 40% of the float, or about 120 million shares, with approximately 10 days to cover, creating the structural conditions for a squeeze if volume expands. Cost to borrow is rising and failures-to-deliver are building, suggesting mounting pressure on short sellers. Read More: 15 AI Stocks That
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- IBRX Stock Jumps on Progress in NK Cell Therapy Production [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) was upgraded by BTIG Research to "strong-buy".MarketBeat
- ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells' [Yahoo! Finance]Yahoo! Finance
- Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge [Yahoo! Finance]Yahoo! Finance
- IBRX Stock: Anktiva's Approvals and What Comes Next [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 2/26/26 - Form 4
- 2/25/26 - Form SCHEDULE
- 2/24/26 - Form 4
- IBRX's page on the SEC website